Drug Profile
Brexpiprazole - Lundbeck/Otsuka
Alternative Names: Lu-AF41156; OPC-34712; OPC-34712 FUM; OPDC-34712; Rexulti; REXULTIOD; RxultiLatest Information Update: 02 Feb 2024
Price :
$50
*
At a glance
- Originator Otsuka Pharmaceutical Development & Commercialization
- Developer Lundbeck A/S; Otsuka Beijing Research Institute; Otsuka Pharmaceutical Development & Commercialization; University of Chicago
- Class Antidepressants; Antipsychotics; Behavioural disorder therapies; Piperazines; Quinolines; Sleep disorder therapies; Small molecules; Thiophenes
- Mechanism of Action Dopamine D2 receptor partial agonists; Serotonin 1A receptor partial agonists; Serotonin 2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Agitation; Major depressive disorder; Schizophrenia
- Phase III Bipolar disorders; Pervasive child development disorders; Post-traumatic stress disorders; Sleep disorders
- Discontinued Attention-deficit hyperactivity disorder; Borderline personality disorders
Most Recent Events
- 24 Jan 2024 Registered for Agitation in Canada (PO)
- 22 Dec 2023 Registered for Major depressive disorder (Adjunctive treatment) in Japan (PO) (Otsuka Pharmaceutical pipeline, February 2024)
- 06 Nov 2023 Efficacy and adverse events data from the phase III Study 213 trial in Agitation (in patients with dementia of the Alzheimer's type) were released by Otsuka Pharmaceutical and Lundbeck Pharmaceuticals